⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
NMRA News
Neumora Therapeutics, Inc. Common Stock
Catalyst Monitor Report: Q1 2026 Outlook: Regulatory Approvals and Late-Stage Trials Signal Strong Pipeline Momentum Across Key Therapeutic Areas
globenewswire.com
GSK
RGNX
OMER
XENE
NMRA
Neumora Therapeutics Highlights 2026 Pipeline Strategy and Anticipated Upcoming Milestones
globenewswire.com
NMRA
Neumora Therapeutics Announces Positive Results from NMRA-511 Phase 1b Signal-Seeking Study in Alzheimer’s Disease Agitation
globenewswire.com
NMRA
Neumora Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
globenewswire.com
NMRA
Neumora Therapeutics to Participate in Upcoming Conferences in November
globenewswire.com
NMRA
Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-898
globenewswire.com
NMRA
Neumora Therapeutics Announces Class-Leading Weight Loss Demonstrated with NMRA-215 in Preclinical Diet-Induced Obesity Model
globenewswire.com
NMRA
Neumora Therapeutics to Host Virtual R&D Day on October 27
globenewswire.com
NMRA